Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma

Cell

Volumn 152, Issue 5, 2013, Pages 1065-1076

  Snuderl, Matija ^a,b,k   Batista, Ana ^a,b   Kirkpatrick, Nathaniel D ^a,b   De Almodovar, Carmen Ruiz ^c,d   Riedemann, Lars ^a,b   Walsh, Elisa C ^a,b   Anolik, Rachel ^a,b   Huang, Yuhui ^a,b   Martin, John D ^a,b   Kamoun, Walid ^a,b   Knevels, Ellen ^c,d   Schmidt, Thomas ^c,d   Farrar, Christian T ^a,b   Vakoc, Benjamin J ^a,b,e   Mohan, Nishant ^a,b,e   Chung, Euiheon ^a,b   Roberge, Sylvie ^a,b   Peterson, Teresa ^a,b   Bais, Carlos ^f   Zhelyazkova, Boryana H ^a   Yip, Stephen ^g   Hasselblatt, Martin ^h   Rossig, Claudia ⁱ   Niemeyer, Elisabeth ^a,b   Ferrara, Napoleone ^f,l   Klagsbrun, Michael ^b,j   Duda, Dan G ^a,b   Fukumura, Dai ^a,b   Xu, Lei ^a,b   Carmeliet, Peter ^c,d   Jain, Rakesh K ^a,b   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f GENENTECH INC   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Institute of Neuropathology   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; NEUROPILIN 1; PLACENTAL GROWTH FACTOR; SONIC HEDGEHOG PROTEIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TISSUE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MEDULLOBLASTOMA; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; STROMA; TUMOR CELL;

EID: 84874760414     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2013.01.036     Document Type: Article

References (47)

1. Bais, C., Wu, X., Yao, J., Yang, S., Crawford, Y., McCutcheon, K., Tan, C., Kolumam, G., Vernes, J.M., Eastham-Anderson, J., et al. (2010). PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141, 166-177.
2. Bielenberg, D.R., Pettaway, C.A., Takashima, S., and Klagsbrun, M. (2006). Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell Res. 312, 584-593.
3. Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307.
4. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001). Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7, 575-583.
5. Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
6. Coenegrachts, L., Maes, C., Torrekens, S., Van Looveren, R., Mazzone, M., Guise, T.A., Bouillon, R., Stassen, J.M., Carmeliet, P., and Carmeliet, G. (2010). Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res. 70, 6537-6547.
7. Dawson, M.R., Duda, D.G., Fukumura, D., and Jain, R.K. (2009). VEGFR1- activity-independent metastasis formation. Nature 461, E4.
8. Dewerchin, M., and Carmeliet, P. (2012). PlGF: A Multitasking Cytokine with Disease-Restricted Activity (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).
9. Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007). Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475.
10. Fischer, C., Mazzone, M., Jonckx, B., and Carmeliet, P. (2008). FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat. Rev. Cancer 8, 942-956.
11. Fouladi, M., Gilger, E., Kocak, M., Wallace, D., Buchanan, G., Reeves, C., Robbins, N., Merchant, T., Kun, L.E., Khan, R., et al. (2005). Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J. Clin. Oncol. 23, 7152-7160.
12. Friedman, H.S., Burger, P.C., Bigner, S.H., Trojanowski, J.Q., Wikstrand, C.J., Halperin, E.C., and Bigner, D.D. (1985). Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J. Neuropathol. Exp. Neurol. 44, 592-605.
13. Friedman, H.S., Burger, P.C., Bigner, S.H., Trojanowski, J.Q., Brodeur, G.M., He, X.M., Wikstrand, C.J., Kurtzberg, J., Berens, M.E., Halperin, E.C., et al. (1988). Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am. J. Pathol. 130, 472-484.
14. Fukumura, D., Duda, D.G., Munn, L.L., and Jain, R.K. (2010). Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17, 206-225.
15. Goel, S., Duda, D.G., Xu, L., Munn, L.L., Boucher, Y., Fukumura, D., and Jain, R.K. (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071-1121.
16. Goldstein, A.M., Yuen, J., and Tucker, M.A. (1997). Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8, 865-871.
17. Hatten, M.E. (1985). Neuronal regulation of astroglial morphology and proliferation in vitro. J. Cell Biol. 100, 384-396.
18. Hatton, B.A., Villavicencio, E.H., Tsuchiya, K.D., Pritchard, J.I., Ditzler, S., Pullar, B., Hansen, S., Knoblaugh, S.E., Lee, D., Eberhart, C.G., et al. (2008). The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res. 68, 1768-1776.
19. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. (1998). Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95, 9349-9354.
20. Jain, R.K., and Xu, L. (2007). alphaPlGF: a new kid on the antiangiogenesis block. Cell 131, 443-445.
21. Lassen, U., Nielsen, D.L., Srensen, M., Winstedt, L., Niskanen, T., Stenberg, Y., Pakola, S., Stassen, J.M., and Glazer, S. (2012). A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br. J. Cancer 106, 678-684.
22. Louis, D.N., Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. (2007). World Health Organization Classification of Tumors of the Central Nervous System (Lyon: IARC Press).
23. Martinsson-Niskanen, T., Riisbro, R., Larsson, L., Winstedt, L., Stenberg, Y., Pakola, S., Stassen, J.M., and Glazer, S. (2011). Monoclonal antibody TB- 403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin. Ther. 33, 1142-1149.
24. Metcalfe, C., and de Sauvage, F.J. (2011). Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 71, 5057-5061.
25. Nielsen, D.L., and Sengelv, L. (2012). Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy. Expert Opin. Biol. Ther. 12, 795-804.
26. Northcott, P.A., Jones, D.T., Kool, M., Robinson, G.W., Gilbertson, R.J., Cho, Y.J., Pomeroy, S.L., Korshunov, A., Lichter, P., Taylor, M.D., and Pfister, S.M. (2012). Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12, 818-834.
27. Pei, Y., Brun, S.N., Markant, S.L., Lento, W., Gibson, P., Taketo, M.M., Giovannini, M., Gilbertson, R.J., and Wechsler-Reya, R.J. (2012). WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development 139, 1724-1733.
28. Pan, Q., Chanthery, Y., Liang, W.C., Stawicki, S., Mak, J., Rathore, N., Tong, R.K., Kowalski, J., Yee, S.F., Pacheco, G., et al. (2007). Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11, 53-67.
29. Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M.L., Segura, I., Li, X., Knevels, E., et al. (2011). HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31-44.
30. Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahan, C.A., Fu, L., Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., et al. (2009). Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178.
31. Rutkowski, S., von Bueren, A., von Hoff, K., Hartmann, W., Shalaby, T., Deinlein, F., Warmuth-Metz, M., Soerensen, N., Emser, A., Bode, U., et al. (2007). Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT91. Clin. Cancer Res. 13, 2651-2657.
32. Schmidt, T., Kharabi Masouleh, B., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., Jonckx, B., De Keersmaecker, K., Kleppe, M., Tjwa, M., et al. (2011). Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 19, 740-753.
33. Taylor, M.D., Northcott, P.A., Korshunov, A., Remke, M., Cho, Y.J., Clifford, S.C., Eberhart, C.G., Parsons, D.W., Rutkowski, S., Gajjar, A., et al. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123, 465-472.
34. Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010). Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178-190.
35. Weekes, C.D., Hegde, P., Xin, Y., Yu, R., Xiang, H., Beeram, M., Gore, L., Brachmann, R.K., and Patnaik, A. (2010). A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors. J. Clin. Oncol. 28, 3014.
36. Walter, K., Omura, N., Hong, S.M., Griffith, M., Vincent, A., Borges, M., and Goggins, M. (2010). Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin. Cancer Res. 16, 1781-1789.
37. Xu, L., and Jain, R.K. (2007). Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol. Cancer Res. 5, 873-880.
38. Xu, L., Cochran, D.M., Tong, R.T., Winkler, F., Kashiwagi, S., Jain, R.K., and Fukumura, D. (2006). Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res. 66, 3971-3977.
39. Yao, J., Wu, X., Zhuang, G., Kasman, I.M., Vogt, T., Phan, V., Shibuya, M., Ferrara, N., and Bais, C. (2011). Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc. Natl. Acad. Sci. USA 108, 11590-11595.
40. Yauch, R.L., Dijkgraaf, G.J., Alicke, B., Januario, T., Ahn, C.P., Holcomb, T., Pujara, K., Stinson, J., Callahan, C.A., Tang, T., et al. (2009). Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326, 572-574.
41. Ziche, M., Maglione, D., Ribatti, D., Morbidelli, L., Lago, C.T., Battisti, M., Paoletti, I., Barra, A., Tucci, M., Parise, G., et al. (1997). Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Laboratory Investigation; a journal of technical methods and pathology 76, 517-531.
42. Chung, E., Yamashita, H., Au, P., Tannous, B.A., Fukumura, D., and Jain, R.K. (2009). Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4, e8316.
43. Jenkins, D.E., Oei, Y., Hornig, Y.S., Yu, S.F., Dusich, J., Purchio, T., and Contag, P.R. (2003). Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin. Exp. Metastasis 20, 733-744.
44. Kamoun, W.S., Ley, C.D., Farrar, C.T., Duyverman, A.M., Lahdenranta, J., Lacorre, D.A., Batchelor, T.T., di Tomaso, E., Duda, D.G., Munn, L.L., et al. (2009). Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27, 2542-2552.
45. Snuderl, M., Fazlollahi, L., Le, L.P., Nitta, M., Zhelyazkova, B.H., Davidson, C.J., Akhavanfard, S., Cahill, D.P., Aldape, K.D., Betensky, R.A., et al. (2011). Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817.
46. Vakoc, B.J., Lanning, R.M., Tyrrell, J.A., Padera, T.P., Bartlett, L.A., Stylianopoulos, T., Munn, L.L., Tearney, G.J., Fukumura, D., Jain, R.K., and Bouma, B.E. (2009). Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat. Med. 15, 1219-1223.
47. Yuan, F., Salehi, H.A., Boucher, Y., Vasthare, U.S., Tuma, R.F., and Jain, R.K. (1994). Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 54, 4564-4568.